KPWS
INDV icon

Kestra Private Wealth Services’s Indivior Pharmaceuticals INDV Stock Holding History

Kestra Private Wealth Services’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
+10,265
New +$372K ﹤0.01% 1339

Other funds holding INDV

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Kestra Private Wealth Services's INDV Position: Q2 2026 in Review

Kestra Private Wealth Services opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 10,265 shares worth $421K. The stake represents ﹤0.01% of the portfolio and ranks #1339 among its holdings.

64 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Kestra Private Wealth Services held 10,265 shares of Indivior Pharmaceuticals worth $421K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Kestra Private Wealth Services position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1339 holding.
  • 64 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.